Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade A 73.87 -0.16% -0.12
SGEN closed down 0.16 percent on Monday, March 25, 2019, on approximately normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical SGEN trend table...

Date Alert Name Type % Chg
Mar 25 20 DMA Support Bullish 0.00%
Mar 25 50 DMA Support Bullish 0.00%
Mar 25 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 25 Doji - Bullish? Reversal 0.00%
Mar 25 Stochastic Reached Overbought Strength 0.00%
Mar 25 Overbought Stochastic Strength 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.16%
Mar 22 Inside Day Range Contraction -0.16%
Mar 21 20 DMA Support Bullish -1.91%
Mar 21 50 DMA Support Bullish -1.91%

Older signals for SGEN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Medicine Biotechnology Cancer Treatment Of Cancer Chemotherapy Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Seattle Genetics Therapies For Cancer Non Hodgkin Lymphoma Renal Cell Carcinoma Adc Metastatic Pancreatic Cancer Castration Resistant Prostate Cancer Cd30 Hodgkin Lymphoma
Is SGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 84.37
52 Week Low 47.75
Average Volume 747,160
200-Day Moving Average 68.8147
50-Day Moving Average 72.0098
20-Day Moving Average 72.5345
10-Day Moving Average 73.441
Average True Range 2.4835
ADX 16.68
+DI 22.9385
-DI 19.4713
Chandelier Exit (Long, 3 ATRs ) 68.2945
Chandelier Exit (Short, 3 ATRs ) 75.2605
Upper Bollinger Band 76.2325
Lower Bollinger Band 68.8365
Percent B (%b) 0.68
BandWidth 10.196527
MACD Line 0.9155
MACD Signal Line 0.7621
MACD Histogram 0.1534
Fundamentals Value
Market Cap 10.56 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -51.66
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 78.81
Resistance 3 (R3) 78.44 76.42 77.98
Resistance 2 (R2) 76.42 75.17 76.61 77.71
Resistance 1 (R1) 75.15 74.39 75.79 75.52 77.43
Pivot Point 73.13 73.13 73.45 73.32 73.13
Support 1 (S1) 71.86 71.88 72.50 72.23 70.31
Support 2 (S2) 69.84 71.10 70.03 70.03
Support 3 (S3) 68.57 69.84 69.76
Support 4 (S4) 68.94